In a year it which it lost £2m of earnings due to the deterioration of its markets and the loss of a major customer, IT software and service consolidator Maxima has still managed to grow impressively.
Selling its wares into over eight different sectors in the mid-market, Maxima partners with software giants Microsoft, SAP, Oracle, Citrix and IBM, which are increasing their market share at the expense of smaller players. Having made 12 acquisitions since floating as a shell in 2004, the company claims its offering is now ‘complete, offering a ‘unique one-stop shop’ for customers with everything from desktop and applications to databases and networks.
But chief executive Kelvin Harrison bristles at a recent slight from venture capitalist John Moulton that Maxima’s is a ‘buy and stack’ strategy, exclaiming that ‘integration is key’. A new sales director and operations director are bringing a ‘more structured and less opportunistic approach’ that has seen cross-selling opportunities increase in the new year.
In the year to May the company completed its 10th and 11th purchases, which contributed partially to revenues rising 47% to £46.7m and profit 24% to £5.2m before tax, 8% of which was organic. Cash conversion improved from 64% to 87% and net debt, after £6.1m was spent on acquisitions, climbed to £8.5m.
Immediately after the year end, Maxima extended its facilities to £17.1m with the acquisition of profitable DXI and retains strong support from Barclays for further deals. Harrison says ‘plenty of further opportunities are out there'.
Recommended here in 2005 at 160p, the shares breached 320p last summer, but have surrendered much ground since. A rating of around five times current year’s earnings suggests little faith exists in the market. This is not entirely warranted and the shares are worth a punt at this price.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
Market cap: £36.51m
PE Forecast: 5.2
Share price: 146p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.